Knight Therapeutics (TSE:GUD) Price Target Raised to C$7.45

Knight Therapeutics (TSE:GUD) had its price objective lifted by Stifel Nicolaus from C$6.25 to C$7.45 in a research report released on Tuesday morning,BayStreet.CA reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the stock. Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Canaccord Genuity Group lowered Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of C$7.48.

Knight Therapeutics Trading Down 0.7 %

Shares of GUD stock opened at C$6.00 on Tuesday. The company has a market capitalization of C$606.90 million, a price-to-earnings ratio of -20.03, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The firm has a 50-day moving average price of C$5.73 and a 200 day moving average price of C$5.59. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.45.

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan sold 2,500,000 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of C$6.30, for a total transaction of C$15,750,000.00. Over the last three months, insiders sold 3,143,300 shares of company stock worth $19,733,740. 45.62% of the stock is owned by company insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.